BR112012027463A2 - método terapêutico, composição farmacêutica, uso de tri-iodotironina (t3) ou de análogo bioquímico da mesma, tri-iodotironina (t3) ou um análogo bioquímico da mesma, e, kit - Google Patents

método terapêutico, composição farmacêutica, uso de tri-iodotironina (t3) ou de análogo bioquímico da mesma, tri-iodotironina (t3) ou um análogo bioquímico da mesma, e, kit

Info

Publication number
BR112012027463A2
BR112012027463A2 BR112012027463A BR112012027463A BR112012027463A2 BR 112012027463 A2 BR112012027463 A2 BR 112012027463A2 BR 112012027463 A BR112012027463 A BR 112012027463A BR 112012027463 A BR112012027463 A BR 112012027463A BR 112012027463 A2 BR112012027463 A2 BR 112012027463A2
Authority
BR
Brazil
Prior art keywords
triiodothyronine
biochemical
kit
pharmaceutical composition
therapeutic method
Prior art date
Application number
BR112012027463A
Other languages
English (en)
Portuguese (pt)
Inventor
Aleck Hercbergs
Osnat Ashur-Fabian
Original Assignee
Aleck Hercbergs
Osnat Ashur-Fabian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aleck Hercbergs, Osnat Ashur-Fabian filed Critical Aleck Hercbergs
Publication of BR112012027463A2 publication Critical patent/BR112012027463A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112012027463A 2010-04-28 2011-04-28 método terapêutico, composição farmacêutica, uso de tri-iodotironina (t3) ou de análogo bioquímico da mesma, tri-iodotironina (t3) ou um análogo bioquímico da mesma, e, kit BR112012027463A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32882510P 2010-04-28 2010-04-28
PCT/IL2011/000346 WO2011135574A1 (en) 2010-04-28 2011-04-28 Methods, compositions and kits for providing a therapeutic treatment

Publications (1)

Publication Number Publication Date
BR112012027463A2 true BR112012027463A2 (pt) 2015-09-29

Family

ID=44860959

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012027463A BR112012027463A2 (pt) 2010-04-28 2011-04-28 método terapêutico, composição farmacêutica, uso de tri-iodotironina (t3) ou de análogo bioquímico da mesma, tri-iodotironina (t3) ou um análogo bioquímico da mesma, e, kit

Country Status (11)

Country Link
US (2) US9655984B2 (cg-RX-API-DMAC7.html)
EP (1) EP2563120B1 (cg-RX-API-DMAC7.html)
JP (1) JP5921529B2 (cg-RX-API-DMAC7.html)
KR (1) KR101841304B1 (cg-RX-API-DMAC7.html)
CN (1) CN102858156B (cg-RX-API-DMAC7.html)
AU (1) AU2011246851B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012027463A2 (cg-RX-API-DMAC7.html)
CA (1) CA2797625C (cg-RX-API-DMAC7.html)
ES (1) ES2791708T3 (cg-RX-API-DMAC7.html)
MX (1) MX2012012479A (cg-RX-API-DMAC7.html)
WO (1) WO2011135574A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120458A1 (en) 2014-02-10 2015-08-13 Fred Hutchinson Cancer Research Center Halogen treatment of heart attack and ischemic injury
CN105486869A (zh) * 2014-10-08 2016-04-13 江苏维赛科技生物发展有限公司 一种检测动物源食品中甲巯咪唑残留的酶联免疫试剂盒及其应用
US20200222348A1 (en) * 2017-05-08 2020-07-16 Musli Thyropeutics Ltd. Bimodal modified release compositions for cancer treatment
WO2021257806A1 (en) * 2020-06-18 2021-12-23 Fred Hutchinson Cancer Research Center Iodide for treatment of nonthyroidal illness syndrome
CN114605278A (zh) * 2022-02-11 2022-06-10 天津市肿瘤医院(天津医科大学肿瘤医院) T3或其可药用盐在制备脑胶质瘤放化疗药物方面的应用
CN114878840A (zh) * 2022-07-12 2022-08-09 昆明思安生物科技有限公司 磁微粒化学发光测定三碘甲状腺原氨酸试剂盒及检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB851610A (en) 1956-03-07 1960-10-19 Gunther Hillman Method for producing iodine derivatives of thyronine
US4426453A (en) 1980-09-18 1984-01-17 Amersham International Limited Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds
JPH07116031B2 (ja) 1986-09-24 1995-12-13 株式会社アドバンス 制癌剤
US6017958A (en) 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
CA2384713A1 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US6939863B2 (en) * 2002-01-04 2005-09-06 Wei-Jan Chen Prevention of atherosclerosis and restenosis
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
EP1929030A2 (en) * 2005-09-08 2008-06-11 Shire LLC Prodrugs of t3 and t4 with enhanced bioavailability

Also Published As

Publication number Publication date
US20130129615A1 (en) 2013-05-23
US9655984B2 (en) 2017-05-23
JP2013525422A (ja) 2013-06-20
KR101841304B1 (ko) 2018-03-22
EP2563120A4 (en) 2015-05-13
KR20130103336A (ko) 2013-09-23
JP5921529B2 (ja) 2016-05-24
US20170274104A1 (en) 2017-09-28
EP2563120B1 (en) 2020-02-26
EP2563120A1 (en) 2013-03-06
CN102858156A (zh) 2013-01-02
ES2791708T3 (es) 2020-11-05
MX2012012479A (es) 2013-07-03
CA2797625A1 (en) 2011-11-03
US10398789B2 (en) 2019-09-03
AU2011246851A1 (en) 2012-11-15
CN102858156B (zh) 2015-09-23
WO2011135574A1 (en) 2011-11-03
CA2797625C (en) 2019-08-20
AU2011246851B2 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
BR112012020304A2 (pt) complexo que alveja tecido, uso de um complexo que alveja tecido, método de tratamento de um corpo de animal humano ou não humano, composição farmacêutica, e, kit
BR112014016672A2 (pt) compostos de carbamato e sua preparação e uso
BR112019000598A2 (pt) rna para terapia de câncer
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
BR112012031163A2 (pt) métodos de terapia combinada para tratamento de doenças proliferativas
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
IN2015DN00376A (cg-RX-API-DMAC7.html)
BR112016013832A2 (pt) Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
BR112015017241A8 (pt) composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit
BR112012009432A2 (pt) anticorpo anti-hsv

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements